Most Read Articles
5 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

3 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
5 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
3 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.

Radical prostatectomy with radiotherapy cuts mortality risk in prostate cancer

28 Sep 2018
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

Radical prostatectomy (RP) with radiotherapy (XRT) reduces the risk of disease-specific death in patients with locally (LAPCa) and regionally advanced (RAPCa) prostate cancer, a recent study shows.

Researchers enrolled 13,856 RAPCa or LAPCa patients, about half of whom were treated with a single modality alone. Most of these patients received RP alone (20.8 percent; n=2,884), followed by XRT (18.3 percent; n=2,541) and androgen deprivation therapy (APT; 11.2 percent; n=1,545) alone.

In comparison, almost 30 percent of the men received multimodal treatment: RP plus XRT (6.1 percent; n=848) and XRT plus ADT (23.6 percent; n=3,272). The remaining 20 percent (n=2,766) did not receive any treatment within 6 months of diagnosis.

After a median follow-up period of 14.6 years, researchers reported 2,189 deaths. Propensity score-adjusted Cox proportional hazards models showed that patients who underwent RP with XRT were less likely to die, both from any and prostate cancer-related causes.

For instance, disease-specific mortalities from T3aN0M0 (adjusted hazard ratio [HR], 4.22; 95 percent CI, 2.83–6.28), T4N0M0 (adjusted HR, 2.31; 1.05–5.12) and T3bN0M0 (adjusted HR, 1.84; 1.34–2.53) malignancies were significantly less likely.

Kaplan-Meier estimates further confirmed the survival benefits associated with RP plus XRT. In men with T3a/bN0-NXM0 disease, the corresponding adjusted 10-year disease-specific survival rates for RP with XRT and ADT with XRT were 88.9 percent and 74.2 percent. The resulting survival difference achieved statistical significance in favour of RP with XRT (difference, 14.7 percent; 11.4–17.2).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

3 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
5 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
3 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.